Introducing Koala Prospector! Bringing Waterfall Enrichment to Reps

Learn More!
Scailyte

Scailyte

Scailyte AG is a spin-off of ETH Zurich and combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers, with a focus on oncology and immunology. Scailyte's proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, in order to identify ultra-sensitive biomarker signatures. Thanks to the single-cell resolution and AI-driven approach, ScaiVision™ is the most powerful and cutting-edge approach to develop methods for precise diagnosis and prediction of therapy response. Scailyte leverages a global network of clinicians to identify disease indications with high unmet needs and collaborates with global pharmaceutical and biotech companies to translate the novel biomarkers into ultra-sensitive companion diagnostics (CDx) and IVD assays.

Last updated on

About Scailyte

Founded

2017

Estimated Revenue

$1M-$10M

Employees

11-50

Funding / Mkt. Cap

$16M

Category

Industry

Biotechnology

Location

City

Cambridge

State

Massachusetts

Country

United States